-
Capital, M&A & Industry Strategy1 month agoSTAT+: Sanofi, Regeneron expand partnership after Dupixent success
Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
-
Capital, M&A & Industry Strategy1 month agoOBIO marks $704m funding milestone for Canadian health tech ventures
The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science...
-
Capital, M&A & Industry Strategy1 month agoTrend of women-led M&A fades in 2026 with just two deals so far
Last year, 11 major M&A deals were signed with women-led biotechs. The industry is nowhere near on track to meet that bar for 2026.
-
Capital, M&A & Industry Strategy1 month agoNovo gets shot at weekly obesity pill as Hengrui gets another MNC deal
BIOCENTURY | DEALSNOVO GETS SHOT AT WEEKLY OBESITY PILL AS HENGRUI GETS ANOTHER MNC DEALNovo adds once-weekly oral GLP1R/GIPR dual agonist for $300M up front
-
Capital, M&A & Industry Strategy1 month agoMerck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue
Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications....
-
Capital, M&A & Industry Strategy1 month agoNovo to pay Hengrui up to $2.6B for a once-weekly obesity pill
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
-
Capital, M&A & Industry Strategy1 month agoHow Cells Respond Differently to a Cancer-Causing Gene
Chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with...
-
Capital, M&A & Industry Strategy1 month agoAstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
-
Capital, M&A & Industry Strategy1 month agoNovo adds long-term obesity differentiation in up to $2.6B Hengrui deal
Investors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral...
-
Capital, M&A & Industry Strategy1 month agoSTAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
Big shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma companies.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
